House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Liver: Hepatic Encephalopathy

ACG · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This ACG guideline addresses hepatic encephalopathy in cirrhosis, from subtle cognitive impairment to acute overt episodes, recurrence prevention and transplant assessment. Diagnosis remains clinical and requires attention to competing explanations and precipitating illness. Treatment combines bowel-directed therapy with nutrition, medication review, reliable support and early reassessment when recovery is incomplete.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Distinguish encephalopathy from its mimics

  • Do not diagnose overt HE from isolated asterixis without behavioural or alertness changes. Evaluate cognitive complaints for alternatives such as sleep apnoea, alcohol-related conditions and mild cognitive impairment, particularly isolated memory or sleep symptoms. [1]
  • For suspected minimal or covert HE, consider a single validated cognitive test rather than requiring two concordant tests (conditional, very low certainty). Use locally appropriate norms and nationally/culturally validated methods; serum ammonia alone cannot diagnose covert HE. [1]
  • Consider lactulose for minimal/covert HE (conditional, low certainty), discussing symptom burden and treatment burden. Routine treatment solely to prevent overt HE has insufficient evidence for a recommendation. Reassess adherence and symptom response after a therapeutic trial of 4–8 weeks before continuing. [1]
  • For altered mental status in cirrhosis, grade severity and evaluate bleeding, infection, sedating drugs, toxic and metabolic contributors. High-grade HE requires appropriate monitored or intensive-care triage and airway assessment. [1]
  • Outpatient care is limited to selected mild, familiar presentations with reliable supervision and no precipitant needing hospital assessment. Agitation, likely nonadherence or absent reliable support rules out outpatient management; first presentations may require emergency evaluation to exclude other causes. [1]
  • Do not routinely use ammonia measurements to titrate HE treatment (conditional, very low certainty); follow clinical recovery. A normal ammonia level in a confused patient should prompt consideration of other diagnoses alongside HE. [1]
  • Routine brain imaging is not suggested for cirrhosis-associated confusion without new focal deficits (conditional, very low certainty). New focal findings, seizures or failure to respond should trigger evaluation for neurological alternatives rather than reflex attribution to HE. [1]

Treat overt episodes and reassess nonresponse

  • Use lactulose for overt HE (strong, moderate certainty), while correcting precipitants. Titrate carefully: excessive catharsis can cause dehydration, electrolyte disturbance and aspiration, which can worsen the clinical course. [1]
  • Consider high-volume polyethylene glycol preparations as an alternative to lactulose for overt HE (conditional, low certainty). Consider adding rifaximin to lactulose for acute overt HE (conditional, low certainty); these recommendations do not replace precipitant management or airway protection. [1]
  • If mental status has not recovered after 48–72 hours of adequate HE treatment and reversal of precipitants, reconsider alternative diagnoses, missed precipitants and portosystemic shunts. Persistent confusion is not a reason simply to increase laxatives indefinitely. [1]

Prevent recurrence with titrated maintenance and support

  • After a first overt episode, use outpatient lactulose titrated to 2–3 soft bowel movements daily (strong, high certainty). Consider stool consistency using the Bristol Stool Scale alongside frequency (conditional, very low certainty), avoiding diarrhoea-related dehydration. [1]
  • Consider outpatient rifaximin to prevent recurrent overt HE (conditional, low certainty). When overt episodes recur despite maintenance lactulose, add rifaximin (strong, high certainty); the discussion describes an adult dose of 550 mg twice daily for recurrence reduction. [1]
  • For persistent overt HE symptoms despite lactulose and rifaximin, consider zinc supplementation only when blood zinc is low (conditional, very low certainty). This is an adjunctive option rather than routine zinc for all HE. [1]
  • Reconcile medications at discharge and review drugs that can worsen cognition or HE risk, including opioids, benzodiazepines, gabapentinoids, sleep medicines and proton-pump inhibitors. Coordinate reductions or cessation with relevant prescribers rather than indiscriminately stopping all medicines. [1]
  • Give patients and caregivers education, assess caregiver burnout and address access or affordability barriers to maintenance therapy. Consider feasible health-information tools to support adherence and communication (conditional, very low certainty). [1]
  • Advise patients with an overt HE episode within the past 3 months, and their caregivers, verbally and in writing to avoid driving. This is expert-consensus advice and does not establish automatic fitness to drive when that interval ends. [1]

Maintain nutrition and muscle function

  • For outpatients with HE, target protein intake of 1.2–1.5 g/kg/day (strong, moderate certainty). Do not restrict protein to treat HE: restriction increases muscle breakdown without shortening the episode (conditional, very low certainty). [1]
  • Use branched-chain amino acid supplements if a person with HE cannot meet protein needs with food alone (strong, moderate certainty). Consider a late-night snack in cirrhosis (conditional, very low certainty); frequent meals and an early breakfast reduce prolonged fasting. [1]
  • Assess muscle health and frailty in all HE, including covert disease. Consider exercise alongside nutritional care (conditional, low certainty), with professional or caregiver supervision because impaired motor skills and responses can increase injury risk. [1]

Escalate selected refractory disease and plan elective TIPS

  • For refractory HE despite optimised therapy, investigate portosystemic shunts. Consider embolisation only with adequate hepatic function and no contraindications (conditional, very low certainty), through a hepatology–radiology decision because varices and ascites may worsen. [1]
  • For decompensated cirrhosis undergoing elective TIPS, start rifaximin 14 days before insertion and continue for at least 6 months, whether or not overt HE occurred previously (strong, moderate certainty). [1]
  • Consider embolising extrahepatic collaterals during TIPS to reduce post-TIPS HE (conditional, low certainty). Treat post-TIPS HE medically; refractory cases may require specialist consideration of TIPS reduction and transplant. [1]
  • For multiple HE episodes with MELD below 15, consider living-donor transplant candidacy evaluation (conditional, low certainty). Severe or frequent HE can justify early transplant assessment despite imperfect capture by MELD; this does not automatically confer allocation points or eligibility. [1]

Limitations and use

  • This summary addresses HE in cirrhosis, not acute liver failure or urea-cycle disorders. Those conditions have different ammonia-directed and critical-care pathways.
  • It does not supply a complete airway, enema, enteral-feeding, transplant-selection or interventional-radiology protocol. Acute treatment needs specialist assessment of route, aspiration risk and fluid balance.
  • Many covert-HE and adjunct-treatment recommendations are conditional. Improvement in cognitive tests or quality of life should not be represented as proven prevention of overt episodes or mortality.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Liver: Hepatic Encephalopathy

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Distinguish encephalopathy from its mimics
  • Treat overt episodes and reassess nonresponse
  • Prevent recurrence with titrated maintenance and support
  • Maintain nutrition and muscle function
  • Escalate selected refractory disease and plan elective TIPS
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House